Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report

Serum sickness, a reaction presenting with a classic triad (fever, rash, myalgia/arthralgia), is considered as a rare adverse event following monoclonal antibodies and specifically following treatment with rituximab. This report describes a case of serum sickness in a newly treated young male patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Khatib, Mohamad Y., Allafi, Solaiman M., Nashwan, Abdulqadir J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869366/
https://www.ncbi.nlm.nih.gov/pubmed/33598239
http://dx.doi.org/10.1002/ccr3.3642
_version_ 1783648616544468992
author Khatib, Mohamad Y.
Allafi, Solaiman M.
Nashwan, Abdulqadir J.
author_facet Khatib, Mohamad Y.
Allafi, Solaiman M.
Nashwan, Abdulqadir J.
author_sort Khatib, Mohamad Y.
collection PubMed
description Serum sickness, a reaction presenting with a classic triad (fever, rash, myalgia/arthralgia), is considered as a rare adverse event following monoclonal antibodies and specifically following treatment with rituximab. This report describes a case of serum sickness in a newly treated young male patient with rituximab for pemphigus vulgaris.
format Online
Article
Text
id pubmed-7869366
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78693662021-02-16 Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report Khatib, Mohamad Y. Allafi, Solaiman M. Nashwan, Abdulqadir J. Clin Case Rep Case Reports Serum sickness, a reaction presenting with a classic triad (fever, rash, myalgia/arthralgia), is considered as a rare adverse event following monoclonal antibodies and specifically following treatment with rituximab. This report describes a case of serum sickness in a newly treated young male patient with rituximab for pemphigus vulgaris. John Wiley and Sons Inc. 2020-12-08 /pmc/articles/PMC7869366/ /pubmed/33598239 http://dx.doi.org/10.1002/ccr3.3642 Text en © 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Khatib, Mohamad Y.
Allafi, Solaiman M.
Nashwan, Abdulqadir J.
Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report
title Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report
title_full Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report
title_fullStr Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report
title_full_unstemmed Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report
title_short Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report
title_sort serum sickness following rituximab therapy in a patient with pemphigus vulgaris: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869366/
https://www.ncbi.nlm.nih.gov/pubmed/33598239
http://dx.doi.org/10.1002/ccr3.3642
work_keys_str_mv AT khatibmohamady serumsicknessfollowingrituximabtherapyinapatientwithpemphigusvulgarisacasereport
AT allafisolaimanm serumsicknessfollowingrituximabtherapyinapatientwithpemphigusvulgarisacasereport
AT nashwanabdulqadirj serumsicknessfollowingrituximabtherapyinapatientwithpemphigusvulgarisacasereport

Ejemplares similares